Vyvanse Should Be Avoided in This Patient
Vyvanse (lisdexamfetamine) is contraindicated in a 67-year-old smoker with high cardiovascular risk due to the combination of serious cardiac disease risk factors and the drug's known cardiovascular effects. The FDA explicitly states to "avoid VYVANSE use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease" 1.
Primary Contraindications and Warnings
FDA Black Box Concerns for High-Risk Cardiac Patients
- Sudden death has been reported in patients with serious cardiac disease treated with CNS stimulants at recommended ADHD dosages 1.
- The FDA label specifically warns against use in patients with "serious cardiac disease," which encompasses the high cardiovascular risk profile of a 67-year-old smoker 1.
- CNS stimulants cause mean increases of 2-4 mmHg in blood pressure and 3-6 bpm in heart rate, with some patients experiencing larger increases 1.
Age-Specific Mortality Risk
- Recent 2025 data demonstrates that stimulant-associated mortality risk increases with age at first use 2.
- Dextroamphetamine (the active metabolite of lisdexamfetamine) showed a relative risk of 3.96 for all-cause mortality in adult populations, with methylphenidate at 4.11 2.
- The self-controlled case series analysis found stimulants as a class had a relative risk of 3.53 for all-cause mortality, with risk escalating in older adults 2.
Cardiovascular Risk Stratification
Smoking as a Compounding Factor
- Smoking is the single most important modifiable cardiovascular risk factor according to 2023 ACC/AHA guidelines 3.
- The combination of stimulant-induced sympathomimetic effects (increased BP and heart rate) with smoking-related endothelial dysfunction and atherosclerotic disease creates multiplicative risk 1, 4.
- Notably, the binge eating disorder trials for Vyvanse specifically excluded patients with cardiovascular risk factors other than obesity and smoking, suggesting the manufacturer recognized smoking as a significant but manageable risk in younger, otherwise healthy populations—not in elderly patients with additional risk factors 1.
High Cardiovascular Risk Profile
- Atherosclerotic heart disease carries the highest odds ratio (36.7) for adverse cardiovascular events in stimulant users 4.
- Hypertension increases odds of adverse events by 2.78-fold in stimulant users 4.
- At age 67, the likelihood of subclinical coronary artery disease, even in asymptomatic individuals, is substantial and may not be detected without formal cardiac evaluation 1.
Comparative Safety Data
Lisdexamfetamine-Specific Evidence
- A 2024 global pharmacovigilance analysis found that lisdexamfetamine showed a weaker association with cardiovascular disease compared to other amphetamines, but still demonstrated increased risk for torsade de pointes/QT prolongation, cardiomyopathy, and myocardial infarction 5.
- The 2022 Danish/Swedish population study showed similar cardiovascular event rates between lisdexamfetamine and other ADHD medications, with incidence rates of 1.40-1.63 per 1000 person-years 6. However, this study population was younger and excluded high-risk cardiac patients 6.
Critical Limitation of Available Evidence
- Most safety studies systematically excluded patients with pre-existing cardiovascular disease or significant risk factors 6, 7.
- The 2012 systematic review noted that studies in adults were more suggestive of safety signals, finding increased risk for transient ischemic attack and sudden death/ventricular arrhythmia 7.
- Adult studies show concerning associations that were not present in pediatric populations, where absolute risk remains low due to absence of underlying cardiovascular pathology 7.
Clinical Decision Algorithm
Mandatory Pre-Treatment Evaluation (If Considering Use Despite Warnings)
- Formal cardiovascular assessment including ECG to rule out structural abnormalities, conduction defects, or QT prolongation 1.
- Stress testing or coronary imaging to exclude significant coronary artery disease in this high-risk patient 1, 4.
- Blood pressure monitoring to ensure hypertension is optimally controlled before any consideration of stimulant therapy 1.
Alternative Management Strategies
- Non-stimulant ADHD medications (atomoxetine, viloxazine, guanfacine, clonidine) should be first-line in patients with contraindications to stimulants 1.
- Smoking cessation is paramount and should be aggressively pursued with varenicline (most effective), bupropion, or nicotine replacement therapy combined with behavioral interventions 3.
- Varenicline has been shown safe in cardiovascular disease populations and increases abstinence rates with relative risk of 1.39 versus bupropion and 1.25 versus NRT 3.
Critical Pitfalls to Avoid
- Do not assume absence of symptoms equals absence of cardiac disease in a 67-year-old smoker—subclinical atherosclerosis is highly prevalent 4.
- Do not rely on younger adult safety data to justify use in elderly patients, as mortality risk demonstrably increases with age at stimulant initiation 2.
- Do not underestimate the cardiovascular stress of even "modest" BP and heart rate increases in patients with compromised cardiovascular reserve 1.
- Do not prescribe without documented cardiovascular clearance if proceeding despite warnings, as this creates medicolegal liability given explicit FDA contraindications 1.
Postmarketing Surveillance Signals
The FDA reports postmarketing cases of cardiomyopathy, chest pain, and cardiovascular death associated with lisdexamfetamine, reinforcing that real-world use reveals risks not fully captured in controlled trials that excluded high-risk patients 1.
The risk-benefit ratio in this specific patient strongly favors avoiding Vyvanse entirely 1, 2, 4.